2025-05-27-Jefferies-Savara_Inc.（SVRA）_美国食品药品监督管理局（FDA）驳回生物制品许可申请（BLA）_将于2025年第四季度重新提交申请并可能引入新的冗余供应商_8页_114kb

Savara Inc. (SVRA) Equity Research Summary

Key Points from the Flash Note

• FDA Action: FDA unexpectedly rejected Savara's (SVRA) BLA submission for Molbreevi (inhaled GM-CSF) for aPAP (aseptic pneumonia). The rejection was due to CMC (Chemical, Manufacturing, and Control) issues.
• Revised Timelines: Refiling expected in Q4 2025. Analysts now believe potential FDA approval could occur in H2 2026, down from YE 2025; however, no change to overall approval probability is expected due to Fujifilm’s tech transfer completion in Fall 2025.
• Recommendation: BUY with a $8.50 price target (+199% upside from $2.84), reflecting long-term confidence.

Big Picture: Analyst Confidence

• Strong Likelihood of Approval: Jefferies is 90%+ confident in Molbreevi approval due to positive Phase III data and durability of response.
• Peak Sales & Valuation: $400M+ peak sales × 4–5x multiple = $1.6B–$2.0B valuation (vs current $~$630M market cap).
• US Market Opportunity: Unmet need in a rare disease, with potential for $350M+ US sales.

CMC Risk (FDA Refusal-to-File)

• FDA Findings: The rejection was solely due to CMC deficiencies, no safety/efficacy concerns.
• Resolution Path: SVRA to request a Type A meeting (30-day approval process likely). Fujifilm has completed 3 upstream PPQ batches and is executing tech transfer.

Fujifilm: New Redundant Supplier

• Strategic Shift: Fujifilm’s timeline was planned for later 2026 but is expedited to Fall 2025. This mitigates supply risk from current supplier GEMA, which is based in Argentina.
• SVRA’s Supplier Diversification: Redundancy is now achieved with two suppliers to enhance reliability for U.S./EU commercialization.

Market Development

• Commercial Strategy: Hiring 50% of 25-member field force by mid-2025 to support potential US launch in 2026.
• Market Opportunity: Tapping into suspected underdiagnosis; achieving $350M+ from 1,000 patients at $350K net price.

Analyst Certification

• All analysts certify independence and no compensation tied to recommendations.

Key Risks Addressed

• Regulatory: FDA timeframe risks, market competition.
• Operational: Reliance on Fujifilm’s timely launch.
• Valuation Drivers: Requires Molbreevi approval and durable US/EU uptake.